-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
For the first time, researchers have found that a class of antifibrotic drugs can slow the progression
of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA).
"Interstitial lung disease is a relatively common complication in patients with rheumatoid arthritis that can progress and cause premature death in 10 percent of such patients," said
Joshua Solomon, M.
Rheumatoid arthritis (RA) is one of the most common autoimmune diseases in the
world.
"With this study, we demonstrate that antifibroid drugs, as a class of drugs, have a reproducible effect in reducing the rate of disease progression when measured by lung capacity," said
Ivan Rosas, Ph.
The National Jewish Health Center is the nation's leading respiratory hospital
.
essay
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study
